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ABSTRACT 
 
Clot Kinetics in the Progression of Cerebral Vasospasm. (December 2009) 
Erin Kathleen Hackney, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Jay D. Humphrey 
 
 
 
 Cerebral vasospasm following subarachnoid hemorrhage has high morbidity and 
mortality. Mathematical modeling of the progression of the condition provides insight to 
improve clinical treatment of patients post subarachnoid hemorrhage. 
 An existing model of the clotting cascade is expanded to include the theoretical 
conditions of cerebral vasospasm. We consider clotting factor XIIIa, which has been 
implicated as a primary cause of the entrenchment of the smaller diameter. Solutions for 
clotting are used as boundary conditions to solve the concentration of diffusible clotting 
factors in the vessel wall and cerebrospinal fluid (CSF).  
Each domain (clot, vessel wall, CSF) is described by a separate initial-boundary 
value problem, requiring unique conditions, reaction-diffusion equations, and diffusion 
coefficients. Additionally, the results from the first domain (the clot) provide a subset of 
the boundary conditions for the second and third domains (arterial wall and CSF, 
respectively). 
Although this approach captures many detailed components of the clotting 
process, a simpler method for investigating the formation and dissolution of a clot post 
subarachnoid hemorrhage is to neglect the bulk of the clot cascade to focus on the most 
 iv
salient features, namely, the formation of cross-linked fibrin and the degradation of 
fibrin by plasmin. By assuming first order kinetics in the initial hours following 
hemorrhage, we find a simplified expression with kinetic rates that may be adjusted 
depending on experimental conditions. 
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1.  INTRODUCTION 
Rupture of an intracranial aneurysm leading to subarachnoid hemorrhage (SAH) 
is the cause of 7% of all strokes (Liu-Deryke and Rhoney, 2006). Vasoactive molecules 
released by the clotting and inflammatory processes cause vasoconstriction in nearby 
arteries within 3 to 4 days following SAH and entrenchment of the smaller lumen 
diameter in 5 to 7 days (Liu-Deryke and Rhoney, 2006). This progression is referred to 
as cerebral vasospasm and occurs in 70% of SAH cases. Cerebral vasospasm causes 
symptomatic ischemia of brain tissue in 36% of SAH cases and increases mortality by 
1.5 to 3 times (Komotar et al., 2007). There are no recognized treatments to prevent 
cerebral vasospasm, and the progression of the condition is not well understood. 
 The products of the formation and dissolution of the clot are important 
contributors to the progression of cerebral vasospasm. Patient outcome is predicted by 
clot clearance rate and clot density (Reilly et al., 2004; Rosen et al., 2007). Following 
the rupture of an aneurysm, blood exits the non-thrombogenic environment of the artery, 
activating platelets and initiating the clotting cascade, a series of biochemical reactions 
with multiple feedback loops. Additionally, the astrocytes and neurons respond to the 
inflammatory process by releasing additional vasoactive molecules. Numerous 
molecules have been implicated in the progression of cerebral vasospasm (Table 1), 
although no definitive list of key molecules has been identified to improve clinical 
treatment following subarachnoid hemorrhage. 
Cerebral vasospasm may be the result of prolonged vasoconstriction, during 
____________ 
This thesis follows the style of Journal of Theoretical Biology. 
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which cellular and structural components re-orient in response to the altered mechanical 
environment, entrenching the smaller diameter. It has been shown that arterial exposure 
to norepinephrine for four hours induces inward eutrophic remodeling in rat cremaster 
muscle arteries (Martinez-Lemus et al., 2004). Martinez-Lemus et al. suggested that “in 
response to prolonged constriction, VSMCs undergo a mechanoadaptation process 
involving ‘length autoregulation’ that would be energetically favorable for maintenance 
of a reduced diameter and may provide a mechanism for the development of eutrophic 
remodeling of the vascular wall” (Martinez-Lemus et al., 2004). 
  
Table 1 
Species which have been suggested as potential culprits in the progression of cerebral vasospasm. 
 
species source effect on wall 
structures references 
ET-1 endothelial cells 
and astrocytes SMC constriction Fassbender et al., 2000 
thrombin blood plasma 
SMC proliferation; 
fibroblast 
proliferation 
Bar-Shavit et al., 1990 
transglutaminase 
(factor XIIIa 
& tTG) 
blood plasma 
and platelets 
cross-linking 
of ECM 
Bakker et al., 2005 
Langille and 
Dajnowjec, 2005 
TGF-beta platelets increased matrix production Flood et al., 2001 
PDGF-AB platelets increased SMC proliferation Zimmermann et al., 2005 
bilirubin 
oxidation 
products 
lysed red 
blood cells SMC constriction 
Clark and Sharp, 2006 
Pyne-Geithman et al., 2005 
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 Here we develop a theoretical framework for a mathematical model which 
describes the time course of the exposure of the arterial wall to vasoactive substances. 
An accurate model may indicate which molecules are of particular importance in 
cerebral vasospasm, allowing clinicians to identify more targeted treatments. We extend 
an existing model (Anand et al., 2008) to describe reaction-diffusion kinetics in the 
cerebrospinal fluid (CSF), clot, and arterial wall and include additional steps of the 
cross-linking of fibrin by activated factor XIII and fibrinolysis. 
 
1.1  Clotting 
Clotting is described by an enzymatic cascade (Figure 1). The intrinsic pathway 
is initiated by contact with damaged vascular tissue, bacteria, or a negatively charged 
surface. The more rapid extrinsic pathway is initiated following trauma by contact with 
tissue factor, which is produced by non-endothelial tissues. The extrinsic pathway 
accounts for the primary source of clotting following subarachnoid hemorrhage. The 
factor VIIa-tissue factor complex activates factor X.  Prothrombinase is produced from 
activated factors V and X, allowing the conversion of prothrombin to thrombin.  
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Fibrin, a 340 kD plasma protein, provides the scaffolding of a mature clot 
(Blomback, 1996). Fibrin is formed from the zymogen fibrinogen by the removal of 
fibrinopeptide A and fibrinopeptide B by thrombin (Blomback, 1996). Tracking the 
appearance of these molecules allows for a description of the rate at which fibrin is 
produced. Alternatively, progression of clot formation can be tracked by monitoring the 
turbidity, or cloudiness, of the clot, which is related to the size of the fibrin fibers 
(Weisel and Nagaswami, 1992). Fibrin is ultimately degraded by plasmin, which cleaves 
the molecule through the process of fibrinolysis, resulting in fibrin degradation products 
(FDPs).  
 
 5
 
Figure 1 
Schema of the clotting cascade. Lines with a bar indicate inhibitory action. Factors in gray are not 
included in the model proposed here. 
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Researchers have attempted to model clot kinetics since the clotting cascade was 
suggested in 1964 by Macfarlane (Macfarlane, 1964).  Some have focused on individual 
steps of activation (Guy et al., 2007; Gir et al., 1996; Nesheim et al., 1992; Weisel and 
Nagaswami, 1992; Ataullakhanov et al., 2002). Others have summarized the major 
contributing species of the entire cascade (Baldwin and Basmadjian, 1994; Hockin et al., 
2002; Khanin and Semenov, 1998; Anand et al., 2003; Anand et al., 2008). Additionally, 
some groups focus on in vitro clotting (Anand et al., 2008; Weisel and Nagaswami, 
1992), while others are concerned with in vivo situations (Anand, 2004; Swaminathan, 
2004; Guy et al., 2006).  
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2.  MODEL DEVELOPMENT 
We extend an existing model to include a potentially important clotting factor, 
Factor XIIIa, and to include the diffusion of clot factors into the vessel wall and CSF. 
We first give a brief explanation of the Anand model and continue with the development 
of the theoretical framework for the proposed model. Figure 2 is a schema of how the 
Anand model applies to the problem of cerebral vasospasm, and Figure 3 illustrates how 
it might be extended to provide clinical insight. A summary of the components necessary 
to complete a well-posed problem for each domain is provided in Appendix B. 
 
 
Figure 2 
Schema of the existing model (Anand et al., 2008), describing reaction and diffusion through the clot with 
no diffusion of products into the vessel wall or CSF. i = 1,…,27. 
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Figure 3 
Schema of the proposed model, including reaction and diffusion of clotting factors through the clot. 
Values at time points at boundaries of the clot provide boundary conditions for the vessel wall and CSF 
solutions. Each medium requires a different set of diffusivity constants for the factors. 
 
 
2.1  Existing Model 
 Anand et al. (2008) introduced a model to describe blood clotting in a quiescent 
state. This model expands on work previously done by the group to describe clot growth 
in flowing blood (Anand et al., 2003). Briefly, the more recent model includes 23 
reaction-diffusion partial differential equations of the form 
 
23,...,1 ,G]Y[]Y[ =+∆=
∂
∂ iiDt i
i
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where i represents each clotting factor of interest. The reaction portion for each factor is 
provided in equations 1-25.  
 
[ ][ ]
[ ]XI11M
XI IIa11G
+
−=
K
k
XI
 (1) 
[ ][ ]
[ ] [ ][ ] [ ][ ]α1AT XIa
1
11ATIII XIa
A3
11XI11M
XI IIa11G Lhh
K
k
XIa −−+
=  (2) 
[ ][ ]
[ ]IX9M
IX XIa9G
+
−=
K
k
IX
 (3) 
[ ][ ]
[ ] [ ][ ]ATIII IXa9IX9M
IX XIa9G h
K
k
IXa −+
=  (4) 
[ ][ ]
[ ]VIII8M
VIII IIa8G
+
−=
K
k
VIII
 (5) 
[ ][ ]
[ ] [ ]
[ ][ ]
[ ]VIIIaC8M
VIIIa APCC8VIIIa8VIII8M
VIII IIa8G
+
−−
+
=
H
h
h
K
k
VIIIa
 (6) 
[ ][ ] [ ]
[ ]X10M
X IXa VIIIa10
G
K
dZk
k
X −=
 (7) 
[ ][ ] [ ]
[ ] [ ][ ] [ ][ ]Xa TFPITFPIATIII Xa10X10M
X IXa VIIIa10
G hh
K
dZk
k
Xa −−=
 (8) 
[ ][ ]
[ ]V5M
V IIa5
VG +
−=
K
k
 (9) 
[ ][ ]
[ ] [ ]
[ ][ ]
[ ]VaC5M
Va APCC5Va5V5M
V IIa5G
+
−−
+
=
H
h
h
K
k
Va
 (10) 
 10
[ ][ ] [ ]
[ ]II2
II Xa Va2
G
+
−=
m
K
dWk
k
II
 (11) 
[ ][ ] [ ]
[ ] [ ][ ]ATIII IIa2II2
II Xa Va2
G h
m
K
dWk
k
IIa −+
=  (12) 
[ ][ ]
[ ]I1
I IIa1G
+
−=
m
K
k
I
 (13) 
[ ][ ]
[ ]
[ ][ ]
[ ]Ia1
Ia PLA1
I1
I IIa1G
+
−
+
=
m
H
h
m
K
k
Ia
 (14) 
[ ][ ]
[ ]PLSPLAM
PLS tPAPLAG
K
k
PLS −=
 (15) 
[ ][ ]
[ ] [ ][ ]α2AP PLAPLAPLSPLAM
PLS tPAPLAG h
K
k
PLA −=
 (16) 
0tPAG =  (17) 
[ ][ ]
[ ]PCPCM
PC IIaPCG
+
−=
K
k
PC
 (18) 
[ ][ ]
[ ] [ ][ ]α1AT APCPC-PCPCM
PC IIaPCG h
K
k
APC +
=  (19) 
[ ] [ ] [ ] [ ] [ ]ATIII XIaA311IIa2Xa10IXa9G  +++−= hhhhATIII  (20) 
[ ][ ]Xa TFPITFPIG hTFPI −=  (21) 
[ ][ ] [ ][ ]α1AT XIaL111α1AT APCPC1G hhAT −−=α  (22) 
[ ][ ]α2AP PLAPLA2G hAP −=α  (23) 
 11
[ ] [ ][ ]
dZk
IXa VIIIaZ =  (24) 
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Reaction kinetics, diffusion coefficients, and initial conditions are determined 
from a literature search, with the results provided in the table in Appendix C, the table 
on page 18, and Appendix A, respectively. The model is solved using a modified version 
of a built-in MATLAB function. The pde solver, pdepe, must be altered to allow for a 
NonNegative requirement, to maintain physically meaningful solutions. Diffusion 
coefficients determined through the method of Young (Young and Bell, 1980) are 
provided in the table on page 18. 
 The model depicts a 2 mm clot (i.e. 0 ≤ x ≤ L, where L = 2 mm) over a period of 
840 seconds (i.e. 0 ≤ t ≤ T, where T = 840 s). A clot is defined as formed when fibrin 
concentration at any point is greater than or equal to 350 nM. Justification for this 
concentration is explained in Anand et al. (2008) and is based on the turbidity, or 
cloudiness, of a clot. The clot is mathematically initiated by setting initial concentrations 
of active factors to 0.1% the value of their inactive zymogen forms (see the table in 
Appendix A). 
For completeness, we briefly list the boundary conditions of the clot (Anand et 
al., 2008). The clot is physically initiated by contact with the thrombogenic surface at x 
= 0 and is mathematically initiated at the boundary
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conditions given in equations 26 and 27. The values for [TF-VIIa] and an explanation of 
the development of these boundary conditions are available in Anand et al., 2008. 
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2.2  Factor XIII  
Factor XIIIa (activated plasma transglutaminase) forms γ-glutamyl-ε-lysyl 
covalent cross-links in mature fibrin (Trumbo and Maurer, 2003). These cross-links 
increase the mechanical strength of the clot as well as the resistance to the degradatory 
effects of plasmin by binding α2-antiplasmin to the fibrin scaffold (Lewis et al., 1997; 
Nielsen, 2006(c)). Factor XIII is produced in zymogen form with A and B subunits by 
macrophages, megakaryocytes, and the liver (Lewis et al., 1997; Lehrer and Ganz, 2001) 
and circulates both in plasma and platelets. Platelets lyse during the clotting process, 
releasing stores of factor XIII, which is quickly activated to form factor XIIIa by the 
removal of the inactive B subunit and exposure of the active site on the A subunit 
(Ariens et al., 2000; Lehrer and Ganz, 2001; Greenberg et al., 2001). 
 Bakker et al. (2005) implicate tissue-type transglutaminase in small artery 
remodeling by its ability to “modify matrix proteins”. They cultured vessels in vitro at 
low pressures to chronically set inner radius low. “However, they have no intrinsic 
tendency to remodel at this pressure” (Bakker et al., 2005). The zymogen for tissue-type 
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transglutaminase (tTG) is composed of two of the A subunits, which are cleaved to 
provide available active sites on each subunit. The activation of factor XIII to factor 
XIIIa follows Michaelis-Menten kinetics (equations 28 and 29). The formation of non-
soluble cross-linked fibrin (IaC) can then be described by equation 30. Equation 30 
includes a constant, C, which accounts for plasmic degradation of cross-linked fibrin 
being significantly slower than that of factor Ia. An appropriate value for this parameter 
is 0.68 (Francis and Marder, 1988). The appropriate kinetic parameters for equations 28-
30 are provided in Table 2. 
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Table 2 
Kinetic parameters for factor XIII and cross-linked fibrin. The activation of factor XIII and the cross-
linking of fibrin follow Michaelis-Menten kinetics with kinetic parameters shown below. 
kinetic 
parameter reaction value source 
k13 XIII → XIIIa 508000 nM Trumbo and Maurer, 2003 
K13M XIII → XIIIa 384 min-1 Trumbo and Maurer, 2003 
k1ac 
Ia → cross-linked 
fibrin 6200 nM Lewis et al., 1997 
K1acM 
Ia → cross-linked 
fibrin 1872 min
-1
 Lewis et al., 1997 
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Additionally, equation 14 is modified to reflect the primary loss of activated 
fibrin due to its cross-linking by factor XIIIa rather than its degradation by plasmin (see 
equation 31). 
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2.3  Diffusion through Clot 
 In the Anand model diffusion coefficients of clotting factors through the clot are 
calculated using the method put forth by Young (Young and Bell, 1980). The factors 
were treated as diffusing through a homogeneous medium. However, diffusion 
coefficients vary with position and time as the clot began to form and fibrin fibrils 
impede the diffusion of molecules. Additionally, the effect of red blood cells in a whole 
blood clot was not considered. These simplifications yield acceptable results (Anand et 
al., 2008), so we carry them through in the current work. Diffusion coefficients in the 
clot are given in the table on page 19. 
 
2.4  Diffusion through Arterial Wall 
 Describing the transport of molecules through an artery wall is of interest in two 
particular fields: drug delivery (Goriely et al., 2007; Hwang and Edelman, 2002; Levin 
et al., 2004) and the diffusion of growth factors into an artery during plaque 
development in atherosclerosis (Dabagh et al., 2007; Fry, 1985; Kim, 1996; Saidel, 
 15
1987; Tarbell, 2003). The transport of molecules through the arterial wall is dependent 
on the wall structure, which varies significantly between arterial beds (e.g. cerebral vs. 
systemic) (Hwang, 2002). 
 In order to understand the progression of cerebral vasospasm we must understand 
the time course and magnitude of the exposure of arterial wall components to vasoactive 
compounds liberated by the clot, neural cells, and inflammatory response. Molecules are 
introduced into the wall from the adventitial side, driven by a concentration gradient and 
moving against the transmural pressure gradient. Total flux includes the diffusive flux 
and the convective flux (Fry, 1985). In cerebral vasospasm the vessel is constricted, 
increasing flow and decreasing pressure. We will neglect the pressure gradient resulting 
from the blood pressure inside the artery, simplifying the flux to the diffusion term only. 
 The wall of an artery is split into three layers (Figure 4). The inner most layer of 
the constricted artery, the intima, is composed of a single leaky layer of endothelial cells. 
The middle layer, or media, is composed of smooth muscle cells, collagen, elastic fibers, 
and proteoglycans, which sequester water. The outermost layer, or adventitia, primarily 
composed primarily of type I collagen, and fibroblasts. The proportion of contents in an 
artery vary by location and function, however cerebral arteries are classified as muscular 
arteries which have a high diffusive resistance in the media (Fry, 1985; Hwang and 
Edelman, 2002). 
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Figure 4 
Typical arterial wall structure. 
 
 
 The internal elastic lamina, which separates the endothelium from the media, acts 
as a physical barrier and reaction site for drugs delivered into the lumen of the artery 
(Goriely, 2007; Creel, 2000). Diffusion across this layer must take into account the area 
of the tissue taken up by pores (Goriely, 2007). This layer of tissue must be accounted 
for in describing diffusion of medicine from the lumen into the artery. However, our 
primary interest is the interaction of the vasoactive species with smooth muscle cells, 
which will be reached before the internal elastic lamellae. 
 Many groups have pursued modeling diffusion across an arterial wall (Goriely, 
2007; Dabagh, 2007; Fry, 1985; Hwang and Edelman, 2002; Kim et al., 1996; Feenstra 
and Taylor, 2009). The effective diffusivity of drugs when applied to the perivascular 
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side are approximately half that of drugs applied to the endovascular side of the artery 
due to the convective effects of transmural pressure (Creel et al., 2000). 
 When all complexities are included each layer of the wall must be accounted for 
separately (Fry, 1985). The endothelium allows transport through endothelial cells and 
pores between cells. In the internal elastic lamina, transport occurs through the sheet and 
through pores in the sheet. Adventitial and medial layers allow transport between cells 
and matrix.  
 As Hwang and Edelman suggest, “because the heterogeneity of the arterial wall 
is highly regular…it is convenient to use a lumped effective diffusivity parameter to 
characterize bulk drug transport properties in the arterial wall” (Hwang and Edelman, 
2002). We treat the arterial wall as a homogeneous continuum composed of a porous 
medium. We neglect the effects of the adventitia and endothelium, calculating effective 
diffusion coefficients through the wall as a function of the void fraction (i.e. the space 
that is not cells and is therefore available for diffusion) of the media. “The adventitia 
itself is a relatively diffuse structure and seems unlikely to present a major barrier” 
(Goriely et al., 2007). For example, the effective diffusivity of heparin in media and 
intima have been shown to be the same and increased in the adventitia (Lovich and 
Edelman, 1999). However, Goriely et al. note that there is an external elastic lamina 
between the adventitia and the media, which would affect diffusivity in a typical artery. 
However, we neglect this barrier, since an external elastic lamina does not exist in 
cerebral arteries. 
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We use the method of Weissberg to determine the effective diffusivity through 
the arterial wall (Weissberg, 1963). The void fraction of the arterial wall is 0.75 (Murata, 
1985) and the viscosity of water is 0.69 cP. The effective diffusion coefficient of each 
species is given in the table on page 19.  
 We assume constant diffusion coefficient as a function of time and space. 
However, as cerebral vasospasm progresses, the structure of the wall would also change 
as the orientation of cells and matrix structures change (Hwang and Edelman, 2002). 
 The basilar artery, a major artery which supplies the brain with blood, is often 
used in studies of cerebral vasospasm. Typical adult human basilar arterial wall 
thickness is approximately 250 µm, which provides a generic value for the diffusion 
distance, Lˆ , through the artery wall (Pico et al., 2006). Further discussion of this value is 
provided in Future Work. 
 
 
 
2.5  Diffusion through CSF 
 
Diffusion coefficients of the clotting factors in the CSF are calculated, once 
again, using the Young method and are given in Table 3 (Young and Bell, 1980).  
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Table 3 
Diffusion coefficients of clotting species in plasma and CSF and effective diffusion coefficients in wall.  
species 
molecular 
mass 
(Da) 
diffusion 
coefficient in 
plasma (cm2/s) 
diffusion 
coefficient in 
water (cm2/s) 
effective 
diffusion 
coefficient in 
wall (cm2/s) 
diffusion 
coefficient in 
CSF (cm2/s) 
fibrinogen (I) 340000 3.1 x 10-7 5.37 x 10-7 3.52 x 10-7 4.36 x 10-7 
fibrin (Ia) 660000 2.47 x 10-7 4.31 x 10-7 2.82 x 10-7 3.50 x 10-7 
prothrombin (II) 72000 5.21 x 10-7 9.01 x 10-7 5.91 x 10-7 7.31 x 10-7 
thrombin (IIa) 37000 6.47 x 10-7 1.13 x 10-6 7.38 x 10-7 9.13 x 10-7 
V 330000 3.12 x 10-7 5.42 x 10-7 3.56 x 10-7 4.40 x 10-7 
Va 179000 3.82 x 10-7 6.65 x 10-7 4.36 x 10-7 5.40 x 10-7 
VIII 330000 3.12 x 10-7 5.42 x 10-7 3.56 x 10-7 4.40 x 10-7 
VIIIa 166000 3.92 x 10-7 6.82 x 10-7 4.47 x 10-7 5.54 x 10-7 
IX 56000 5.63 x 10-7 9.80 x 10-7 6.42 x 10-7 7.95 x 10-7 
IXa 41000 6.25 x 10-7 1.09 x 10-6 7.13 x 10-7 8.83 x 10-7 
X 56000 5.63 x 10-7 9.80 x 10-7 6.42 x 10-7 7.95 x 10-7 
Xa 25000 7.37 x 10-7 1.28 x 10-6 8.41 x 10-7 1.04 x 10-6 
XI 160000 3.97 x 10-7 6.91 x 10-7 4.53 x 10-7 5.61 x 10-7 
Xia 80000 5.0 x 10-7 8.70 x 10-7 5.70 x 10-7 7.06 x 10-7 
XIII 320000 3.15 x 10-7 5.48 x 10-7 3.59 x 10-7 4.45 x 10-7 
XIIIa 166000 3.92 x 10-7 6.82 x 10-7 4.47 x 10-7 5.54 x 10-7 
a1AT 51000 5.82 x 10-7 1.01 x 10-6 6.63 x 10-7 8.21 x 10-7 
tPA 68000 5.28 x 10-7 9.18 x 10-7 6.02 x 10-7 7.46 x 10-7 
plasminogen 92000 4.81 x 10-7 8.30 x 10-7 5.44 x 10-7 6.74 x 10-7 
plasmin 85000 4.93 x 10-7 8.53 x 10-7 5.59 x 10-7 6.92 x 10-7 
a2AP 70000 5.25 x 10-7 9.10 x 10-7 5.96 x 10-7 7.38 x 10-7 
PC 62000 5.44 x 10-7 9.47 x 10-7 6.21 x 10-7 7.69 x 10-7 
APC 60000 5.50 x 10-7 9.58 x 10-7 6.28 x 10-7 7.77 x 10-7 
ATIII 58000 5.57 x 10-7 9.68 x 10-7 6.35 x 10-7 7.86 x 10-7 
TFPI 40000 6.30 x 10-7 1.10 x 10-6 7.19 x 10-7 8.90 x 10-7 
 
 
2.6  Flux between Domains 
 The flux between each domain forms a unique set of boundary conditions for 
each domain (Figure 5).  
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Figure 5 
Schema of the boundary conditions that exist at the interface between each domain. 
  
Flux of clotting factors from the clot to the arterial wall occur over a permeable 
solid-permeable solid interface (Truskey et al., 2004), which can be described by 
 






−Φ=
∂
∂
wall
C
clot
CC iiikt
i
 (32) 
 
where Ci is the concentration of each species at the boundary, and k is the permeability 
coefficient, defined as 
L
effDk
Φ
=  (33) 
The partition coefficient, Φ, is defined as 
ε
AVk
=Φ  (34) 
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where  
 
 volumetotal
  volumeavailable
=AVk  (35) 
 
and 
 
 volumetotal
 volumevoid
=ε  
 
Therefore, 
 
 volumevoid
 volumeavailable
 volumetotal
 volumevoid
 volumetotal
  volumeavailable
==Φ  (36) 
 
 
 Void volume is defined as the volume of the permeable solid that is vacant of 
solid material and able to contain diffusing substances. Available volume is defined as 
the volume of the permeable solid that is accessible from other gaps. We select the 
conservative estimate of Φ, as the material with the lower value would potentially act as 
a limiting factor in the rate of diffusion. 
Similarly, flux from the clot into the CSF can be described as occurring at a 
permeable solid-liquid interface (Truskey et al, 2004). Therefore, 
 






−Φ=
∂
∂
CSF
C
clot
CC iiikt
i
. (37) 
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 We neglect any transfer that occurs between the lumen of the artery and the 
arterial wall, although this could also be described with the permeable solid-liquid 
interface form. 
 
2.7  Reaction with Wall Components 
 As each species diffuses into the arterial wall, reactions occur with the 
extracellular matrix and cells (e.g. fibroblasts, smooth muscle cells, endothelial cells), 
impeding the flux through the wall. Thrombin, a smooth muscle cell mitogen, is used 
here to illustrate the reaction of one of the species with wall components. The general 
form for the reaction component, G, for thrombin in the artery wall is given below. 
 
[ ]
[ ]IIa11M
IIa ]sitesreaction  SMC[
G
+
−=
K
dk
IIa
 (38) 
 
where [ ] 





=
SMC
sitesreaction  
 SMC]sitesreaction   SMC[  
 
Dabagh et al.(2007) estimate the volume fraction of smooth muscle cells, [SMC], 
to be 0.4 – 0.7. Additional experiments would have to be performed to confirm that 
Michaelis-Menten kinetics are appropriate for this reaction and to determine the kinetic 
constants, kd and K11M.  
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3. STRUCTURE OF PROGRAM 
 Each domain (i.e. the clot, arterial wall, and CSF) is solved using separate code. 
Each domain is defined by its boundary conditions, initial conditions, and reaction-
diffusion equations, which are then solved by a modified pdepe code. Each domain 
yields a program flow as shown in Figure 6. Figure 7 shows a schematic of the entire 
program, illustrating the output of the clot domain providing boundary conditions for the 
CSF and vessel wall domains. The required form for each domain is provided in the 
tables in Appendix B. 
 
 
Figure 6 
Flow of program for each domain. 
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Figure 7 
Schema of flow of entire model. Includes the feed of solutions from the clot domain into the initial 
conditions for the CSF and vessel wall domains. 
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4.  RESULTS OF SIMPLIFIED APPROACH 
 Although this system of partial differential equations captures many interesting 
and important details about the clotting process in subarachnoid hemorrhage and can be 
used to describe numerous pathological conditions (see Anand et al., 2003 and Anand et. 
al, 2008), we can greatly simplify the kinetics by describing these reactions with first 
order reactions representing lumped parameter models. This essentially is allowed by 
assuming that an excess quantity of the substrate and the enzyme are present so that 
there is no rate limiting reactant.  
 Two particular subgroups of the cascade emerge as central for the cerebral 
vasospasm problem. First, the rate at which the clot is degraded by plasmin is important 
for understanding the exposure of the adjacent artery to clot factors (see Figure 8). 
Second, the formation of the clot, with particular emphasis on the crosslinking of fibrin 
by transglutaminase (factor XIIIa) provides the time course for the clot becoming 
insoluble (see figure on page 30). 
 
4.1  Degradation of Cross-linked Fibrin 
 For the first reaction of interest (Figure 8) we perform nonlinear regression. The 
data given in Figure 9 are reproduced from Figure 3 of Wootton et al., 2001. We focus 
on the experimental results at low shear rates (4 dyn/cm2) to best represent the stagnant 
blood following subarachnoid hemorrhage. 
 26
 
Figure 8 
Schema of reaction which yields fibrin fragments through degradation of fibrin by plasmin. 
 
Assuming first-rate kinetics, these reactions are described mathematically as, 
 
]pls][tPA[]pla[ 1kdt
d
=  
dtkdt
dt
d ss
∫∫ = 0 10 ]pls][tPA[
]pla[
 
∫=
s
s
dtk
01
]pls[]tPA[]pla[
 (39) 
 
and 
 
]pla][Iac[]FDP[ 2kdt
d
=  
∫∫ =
ss
dtkdt
dt
d
0 20
]pla][Iac[]FDP[  
∫=
s
s
dtk
02
]pla[]Iac[]FDP[
 (40) 
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With substitution, 
∫ ∫=
s s
s
dtdtkk
0 012
]pls[]tPA][Iac[]FDP[
 
∫=
s
s
dtkk
dt
d
012
]pls[]tPA][Iac[]FDP[  
]pls][tPA][Iac[]FDP[ 122
2
kk
dt
d
s
=  (41) 
 
 The loss of fibrin through degradation by plasmin assumes a sigmoidal shape 
experimentally (Figure 9) (Wootton et al., 2001), which takes the form 
 
m
gb
a
kh ++
=
+− te
]FDP[
 (42) 
 
Using the Matlab built-in function lsqcurvefit, which employs the Levenberg-
Marquardt algorithm, we solve for the values of each parameter to determine an equation 
to describe the degradation of fibrin (Iac) (Appendix D). Results of the fit are given in 
Figure 9. 
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Figure 9 
Fibrin loss due to degradation by plasmin. Experimental (*) results reproduced from Wootton et al., 2001, 
Figure 3. Predicted values (o) determined from nonlinear regression. 
 
 
 
Results of nonlinear regression yield 
 
a = 0.0184 
b = 0.0198 
g = 1.9018 
h = 0.1679 
k = 4.8323 
m = -0.0368 
 
with a norm of residuals of 0.0017, or 
 
 
[ ] 0368.0
e9018.10198.0
0184.0FDP 8323.41679.0 −+
=
+− t
 (43) 
 
 
and, therefore, 
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   ]pls][tPA][Iac[12kk=  
 
 
 
Therefore, 
 
( )
( )
( )
( )
]pls][tPA][Iac[
e9018.1019847.0
e00098776.0
                           
]pls][tPA][Iac[
e9018.1019847.0
e0037570.0
28323.4t16788.0
28323.4t16788.0
38323.4t16788.0
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12
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+−
+−
+
−
+
=kk
 (45) 
 
We assume that plasminogen (pls) and tPA are not consumed in the reaction and 
are available in sufficient quantities to prevent any rate-limiting effects.  Therefore, [pls] 
= [pls]o and [tPA]=[tPA]o. If we were to consider the behavior over long periods we 
would have to account for the half-lives of each molecule, but we neglect that 
complication here.  
tPA is injected at an initial concentration of 6.94 µM (0.5 µg/ml). The initial 
plasminogen would be based on the PPP (platelet-poor plasma) sample. Since we neglect 
the more complicated requirements of a solution where feedback is considered, [Iac] is 
also treated as a constant value, which is determined by the experimental conditions. 
Wootton et al. did not report this value, but the experiment could be repeated to confirm 
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the value. In this case we are unable to separate the values of k1 and k2, as more 
experiments would be required. However, this lumped sum parameter solution is 
sufficient for continuum mixture models. 
 
4.2  Formation of Cross-linked Fibrin 
 The second set of reactions of interest (Figure 10) are described following a 
similar process as given above.  
 
 
Figure 10 
Schema of fibrinogen being converted through two reactions to cross-linked fibrin. 
 
 
]IIa][I[]Ia[ 1kdt
d
=  
dtkdt
dt
d ss
∫∫ = 0 10 ]IIa][I[
]Ia[
 
∫=
s
s
dtk
01
]I[]IIa[]Ia[
 (46) 
 
Similarly, 
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]XIIIa][Ia[]Iac[ 2kdt
d
=  
∫∫ =
ss
dtkdt
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0 20
]XIIIa][Ia[]Iac[  
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s
s
dtk
02
]Ia[]XIIIa[]Iac[
 (47) 
 
where we similarly assume that 0]XIIIa[]XIIIa[ =  and 0]IIa[]IIa[ = . 
 In contrast to the degradation reactions, the solution to these staggered reactions 
may be solved in two steps, in order to define k1 and k2 independently. Weisel et al. 
(1992) provide a solution to describe the formation of fibrin (I) beginning from the 
conversion from fibrin. This solution yields a sigmoidal shape (Figure 11) which is most 
appropriately modeled as 
 
d
cba te]Ia[ +=
 (48) 
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Figure 11 
Fraction of activated fibrin formed in the presence of thrombin (factor IIa). Experimental (*) results 
reproduced from Weisel and Nagaswami, 1992, Figure 2. Predicted values (o) determined from nonlinear 
regression. 
 
Results of the nonlinear regression yield 
a = 0.9036 
b = -0.9111 
c = -0.4642 
d = 1.7811 
 
with a norm of residuals of 0.0057, or 
 
7811.1t4642.0e9111.09036.0]Ia[ −−=  (49) 
 
Therefore, 
 
[ ] 7811.1t4642.0t7811.0 et7533.0Ia −=
dt
d
 (50) 
 
and, from equations 45 and 49, 
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]I][IIa[
et7533.0
7811.1t4642.0t7811.0
1
−
=k  (51) 
where [IIa] is about 1 NIH unit/mL  and [I] = 0.5-1.5 mg/ml  (Weisel, 1992). Additional 
experiments should be performed to narrow possible initial values. 
 The formation of the final product, Iac, assumes a sigmoidal shape 
experimentally (Figure 12) (Siebenlist et al., 2001), which also takes the form 
 
d
cba te]Iac[ +=
 (52) 
 
 
Figure 12 
Percent insoluble fibrin formed in the presence of transglutaminase (factor XIIIa). Experimental (*) results 
reproduced from Siebenlist et al., 2001, Figure 4. Predicted values (o) determined from nonlinear 
regression. 
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 The nonlinear regression yields 
 
a = 96.1 
b = -1066.2 
c = -2.404 
d = 0.2140 
 
with a norm of residuals of 34.8750, or 
 
214.0t404.2e2.10661.96]Iac[ −−=
 (53) 
 
Therefore, 
[ ] 2140.0t404.2t7860.0 et8.548Iac −−=
dt
d
 (54) 
and, from equations 46 and 53, 
 
]Ia][XIIIa[
et8.548
2140.0t404.2t7860.0
2
−−
=k
 (55) 
 
where [XIIIa] = 100 Loewy u/ml and [Ia] is provided by the solution in equation 48 
(Siebenlist, 2001). 
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5.  FUTURE WORK 
 Simplifying assumptions are made in the proposed model to allow for 
computational ease. Here we provide a list of future complexities that may be added to 
the model.  
 As noted in the table on page 2, multiple molecules have been implicated as 
primary in the progression of cerebral vasospasm. The proposed model focuses on 
members of the clotting cascade. Future models should be extended to include additional 
molecules that are released by blood components, neural tissue, and the imflammatory 
process, such as PDFG-AB, Endothelin-1, TGF-β, bilirubin oxidation products, and 
nitric oxide. Molecules with the strongest tissue response for vasoconstriction, 
vasodilation, and smooth muscle cell proliferation are of particular importance. 
 The proposed model treats the arterial wall as a homogeneous medium composed 
of smooth muscle cells and water. As discussed previously, the composition of the 
arterial wall varies with depth and includes additional cells (e.g. endothelial cells and 
fibroblasts) and structural components (e.g. types I, III, and IV collagen and elastic 
fibers). Each structure and cell interacts uniquely with each molecule of interest, acting 
as potentially both physical barriers and reaction sites. 
Diffusion rates would also vary through each layer, depending on the density of 
cells and structural components. Including blood pressure would resist the diffusion of 
products from the adventitial to endothelial surfaces. 
 As cerebral vasospasm progresses the geometry of the wall changes, affecting the 
travel distance of each species. Additionally, smooth muscle cell proliferation increases 
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smooth muscle cell density, resulting in an increasing consumption of molecules of 
interest. 
 The supply and loss of each clotting factor is dependent on the complex channel 
system within a whole blood clot (Adolph et al., 1997). These networks of caniculi, as 
described by Adolph et al., in particular affect the rate of fibrinolysis of the clot, based 
on supply of tPA and uPA to the interior of the clot. Additionally, although the CSF is 
treated essentially as a sink for all clotting factors at the outer edge of the clot, the 
constant flow of CSF would increase the rate at which factors are flushed from the area, 
increasing the concentration gradient across the barrier and, by extension, an increased 
loss of all species. 
 As mentioned previously, initial clot volume is a factor in predicting the clinical 
outcome of an SAH patient. Altering the thickness of the clot (i.e. the L value in the clot 
domain) and the thickness of the artery wall (i.e. the Lˆ value in the artery wall domain) 
provides patient specific predictions of concentrations within the artery wall. 
 Improvements can be made in the proposed simplified models by repeating the 
reported experiments to confirm precise concentrations of each reactant used. Additional 
experiments could be used to confirm the robustness of the model. 
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6.  CONCLUSION 
Cerebral vasospasm following subarachnoid hemorrhage is a leading cause of 
morbidity and mortality following patient survival of the initial bleed. Using 
mathematical modeling to predict the concentration of vasoactive molecules through the 
time course of vasospasm will provide the insight to determine which molecules are of 
primary importance in the progression of the condition, allowing clinicians to treat 
subarachnoid hemorrhage patients by addressing the root cause. 
 Here we develop the theoretical framework for a mathematical model to describe 
the diffusion of vasoactive substances from a clot into the arterial wall following 
subarachnoid hemorrhage. The initial approach, containing a system of 26 PDEs, is a 
comprehensive and complicated method for describing the clot kinetics involved in the 
progression of cerebral vasospasm. However, with simplified kinetics and a focus on 
fewer equations we are able to elucidate sufficient parameters for a continuum mixture 
model in the initial stages of clotting following subarachnoid hemorrhage. 
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APPENDIX A 
Table 4 
Initial concentrations in plasma. The initial concenration of factor XIIIa is determined by the same method 
as Anand et al., 2008 (i.e. initializing the active factor at a concentration of 0.1% of that of the zymogen). 
Cross-linked fibrin is not present until factor XIIIa catalyzes the formation of the cross-links from factor 
Ia. 
 
i species initial concentration in plasma (nM) source 
1 IXa 0.09 Anand et al., 2008 
2 IX 90 Anand et al., 2008 
3 VIIIa 0.0007 Anand et al., 2008 
4 VIII 0.7 Anand et al., 2008 
5 Va 0.02 Anand et al., 2008 
6 V 20 Anand et al., 2008 
7 Xa 0.17 Anand et al., 2008 
8 X 170 Anand et al., 2008 
9 IIa 1.4 Anand et al., 2008 
10 II 1400 Anand et al., 2008 
11 Ia 7 Anand et al., 2008 
12 I 7000 Anand et al., 2008 
13 XIa 0.03 Anand et al., 2008 
14 XI 30 Anand et al., 2008 
15 ATIII 3400 Anand et al., 2008 
16 TFPI 2.5 Anand et al., 2008 
17 APC 0.06 Anand et al., 2008 
18 PC 60 Anand et al., 2008 
19 L1AT 45000 Anand et al., 2008 
20 tPA 0.08 Anand et al., 2008 
21 PLA 2.18 Anand et al., 2008 
22 PLS 2180 Anand et al., 2008 
23 L2AP 105 Anand et al., 2008 
24 XIII 187.5 Furie and Furie, 2000 
25 XIIIa 0.1875 n/a 
26 
cross-linked 
fibrin 
0 n/a 
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APPENDIX B 
 
Table 5  
Code requirements for clot domain. 
domain #1: clot 
code requirement source 
boundary conditions at x = 0 for i = 1, …, 26, found in Anand et al., 2008 
boundary conditions at x = L for i = 1, …, 26, found in Anand et al., 2008 
initial conditions 
for i = 1, …, 23, found in Anand et al., 2008 
for i = 24,…,26,  found in literature search (see Table 4 in 
Appendix A) 
reaction-diffusion equations 
for i = 1, …, 23, found in Anand et al., 2008 
for i = 24,…,26, found in literature search described in 
section 2.2: Factor XIII  
(see Equations 1 - 30) 
diffusion coefficients 
for i = 1,…,23, found in Anand et al., 2008 
for i = 24, 25, calculated using Young and Bell, 1980 
method as described in section 2.3:  Diffusion through Clot 
on page 14 
for i = 26, diffusion coefficient = 0 
(see Table 3 on page 19) 
 
 
 
Table 6 
Code requirements for arterial wall domain. 
domain #2: arterial wall 
code requirement source 
boundary conditions at 0xˆ =  solution from clot domain at x = 0 (output A) (see Figure 7 on page 25) 
boundary conditions at Lˆxˆ =  for i = 1,…,25, [i] = 0 
initial conditions for i = 1,…,25, [i] = 0 
reaction-diffusion equations 
for i = 9, defined by reaction of thrombin with SMCs as 
explained in section 2.7: Reaction with Wall Components 
on page 22 
diffusion coefficients 
for i = 1,…,25, determined by method of Weissberg, 1963 
as described in section 2.4:  Diffusion through Arterial 
Wall on page 14 
(see Table 3 on page 19) 
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Table 7  
Code requirements for CSF domain. 
domain #3:CSF 
code requirement source 
boundary conditions at  0x~ =  solution from clot domain at x = L (output B) (see Figure 7 on page 25) 
boundary conditions at L~x~ =  for i = 1,…,25, [i] = 0 
initial conditions for i = 1,…,25, [i] = 0 
reaction-diffusion equations 
for i = 1,…,25, no reaction occurs and CSF acts as an 
infinite sink as described in section 2.5: Diffusion into CSF 
on page 18 
diffusion coefficients 
for i = 1,…,25, determined by method of Young and Bell, 
1980 as described in section 2.5:  Diffusion into CSF 
(see Table 3 on page 19) 
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APPENDIX C 
 
Table 8 
Kinetic parameters from Anand et al., 2008. 
kinetic parameter reaction value 
k11 XI → XIa 0.0078 min-1 
K11M XI → XIa 50 nM 
h11A3 XI → XIa 1.6 x 10-3 nM-1 min-1 
h11L1 XI → XIa 1.3 x 10-5 nM-1 min-1 
k9 IX → IXa 11 min-1 
K9M IX → IXa 160 nM 
h9 IX → IXa 0.0162 nM-1 min-1 
k8 VIII → VIIIa 194.4 min-1 
K8M VIII → VIIIa 112000 nM 
h8 VIII → VIIIa 0.222 min-1 
hC8 VIII → VIIIa 10.2 min-1 
HC8M VIII → VIIIa 140.5 nM 
KdZ Z (tenase) 0.56 nM 
k5 V → Va 27.0 min-1 
K5M V → Va 140.5 nM 
h5 V → Va 0.17 min-1 
hC5 V → Va 10.2 min-1 
HC5M V → Va 14.6 nM 
k10 X → Xa 2391 min-1 
K10M X → Xa 160 nM 
h10 X → Xa 0.347 nM-1 min-1 
hTFPI X → Xa 0.48 nM-1 min-1 
KdW W (prothrombinase) 0.1 nM 
k2 II → IIa 1344 min-1 
K2M II → IIa 1060 nM 
h2 II → IIa 0.714 nM-1 min-1 
kPC PC → APC 39 min-1 
KPCM PC → APC 3190 nM 
hPC PC → APC 6.6 x 10-7 nM-1 min-1 
k1 I → Ia 3540 min-1 
K1m I → Ia 3160 nM 
 48
kinetic parameter reaction value 
h1 I → Ia 1500 min-1 
H1m I → Ia 250000 nM 
kPLA PLA → PLS 12 min-1 
KPLAm PLA → PLS 18 nM 
hPLA PLA → PLS 0.096 nM-1 min-1 
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APPENDIX D 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
% deg.m 
% degradation of fibrin 
% use with myfun.m 
  
clear;clc;close all; 
  
% data recreated from Wootton, 2001, Figure 3 
time = [0,3,6,9,12,15,18,21,24,27,30,33,36,39]; 
loss = [0,0.005,0.01,0.03,0.1,0.18,0.26,0.39,0.5,0.59,0.68,0.76,0.8,0.85]; 
% fibrin loss (relative to 1) 
% at 4 dyn/cm^2 shear 
  
lb = []; % must pass empty lower bounds matrix to define options 
ub = []; % must pass empty upper bounds matrix to define options 
options = optimset('MaxFunEvals',1000,'TolFun',.00001); 
x0 = [1;1;1;1;5;0]; % initial guess of parameters 
[x,resnorm] = lsqcurvefit(@myfun, x0,time,loss,lb,ub,options) 
  
mod = x(1)./(x(2) + x(3)*exp(-x(4).*(time+x(5)))) + x(6); 
  
plot(time,loss,'*',time,mod,'o') 
xlabel('time (minutes)') 
ylabel('Fibrin Loss') 
legend('experimental','predicted','Location','NorthWest') 
axis([0 40 0 1.0]) 
  
a = x(1); b = x(2); g = x(3); h = x(4); k = x(5); m = x(6); 
syms indep 
est = a/(b + g*exp(-h*indep + k)) + m; 
first = diff(est); 
second = diff(first); 
second = vpa(second,5); 
pretty(second) 
 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
% for use with def.m 
% myfun.m 
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function F = myfun(x,t) 
  
F = x(1)./(x(2) + x(3)*exp(-x(4)*(t+x(5)))) + x(6); 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
% kl.m 
% Fibrinogen (I) -> Fibrin (Ia) 
% use with myfun.m 
  
clear;clc;close all; 
  
% data recreated from Weisel, 1992, Figure 2 
time = linspace(0,300,7)./60; 
clot = [0,0.23,0.65,0.80,0.85,0.89,0.95]; 
% fraction of mature fibrin 
  
lb = []; % must pass empty matrix of lower bounds to define options 
ub = []; % must pass empty matrix of upper bounds to define options 
options = optimset('MaxFunEvals',1000,'TolFun',.00001); 
x0 = [0;1;1;1]; % initial guess of parameters 
[x,resnorm] = lsqcurvefit(@myfun, x0,time,clot,lb,ub,options) 
  
mod = x(1) + x(2)*exp(x(3)*time.^x(4)); 
  
plot(time,clot,'*',time,mod,'o') 
xlabel('time (minutes)') 
ylabel('fraction of activated fibrin (I)') 
legend('experimental','predicted','Location','East') 
axis([0 5 0 1]) 
  
syms indep 
est = x(1) + x(2)*exp(x(3)*indep^x(4)); 
first = diff(est); 
first = vpa(first,4) 
pretty(first); 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
% myfun.m 
% for use with kl.m 
  
function F = myfun(x,t) 
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F = x(1) + x(2).*exp(x(3).*t.^x(4)); 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
% k2.m 
% Fibrin (I) -> crosslinked fibrin (Iac) 
% for use with myfun.m 
  
clear;clc;close all; 
  
% data recreated from Siebenlist, 2001, Figure 4 
time = [1,5,10,15,20,25,30,35,40,45,50,55,60,90]; 
insol = [0,58,80,82,84,86,88,89,90,91,92,93,94,95]; 
% percent insoluble fibrin (Iac) 
  
lb = []; % must pass empty matrix of lower bounds to define options 
ub = []; % must pass empty matrix of upper bounds to define options 
options = optimset('MaxFunEvals',1000,'TolFun',.00001); 
x0 = [0;100;.5;.5]; % initial parameter guess 
[x,resnorm] = lsqcurvefit(@myfun, x0,time,insol,lb,ub,options) 
  
mod = x(1) + x(2)*exp(x(3)*time.^x(4)); 
  
plot(time,insol,'*',time,mod,'o') 
xlabel('time (minutes)') 
ylabel('percent insoluble fibrin') 
legend('experimental','predicted','Location','East') 
axis([0 90 0 100]) 
  
syms indep 
est = x(1) + x(2)*exp(x(3)*indep^x(4)); 
first = diff(est); 
first = vpa(first,4) 
pretty(first); 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
% myfun.m 
% for use with k2.m 
  
function F = myfun(x,t) 
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F = x(1) + x(2)*exp(x(3)*t.^x(4)); 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 53
VITA 
 
Name: Erin Kathleen Hackney 
Address: 337 Zachry Engineering Center 
 3120 TAMU 
 College Station, TX 77843-3120 
 
Email Address: erkjohnson@gmail.com 
 
Education: B.S., Biomedical Engineering, Texas A&M University, 2007 
 M.S., Biomedical Engineering, Texas A&M University, 2009 
